Manufacturer of Controlled Substances; Notice of Application, 36728 [E7-12978]
Download as PDF
36728
Federal Register / Vol. 72, No. 128 / Thursday, July 5, 2007 / Notices
DEA to manufacture such a substance
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections being sent via regular mail
should be addressed, in quintuplicate,
to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), Washington, D.C. 20537, or any
being sent via express mail should be
sent to Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 2401 Jefferson Davis Highway,
Alexandria, Virginia 22301; and must be
filed no later than September 4, 2007.
Dated: June 26, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–12976 Filed 7–3–07; 8:45 am]
BILLING CODE 4410–09–P
Dated: June 26, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–12955 Filed 7–3–07; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
sroberts on PROD1PC70 with NOTICES
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on March 2, 2007,
Amri Rensselaer, Inc., 33 Riverside
Avenue, Rensselaer, New York 12144,
made application by letter to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
Lisdexamfetamine (1205), a basic class
of controlled substance listed in
schedule II.
The company plans to manufacture
the listed controlled substance in bulk
for sales to its customer.
Any other such applicant and any
person who is presently registered with
DEA to manufacture such a substance
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections being sent via regular mail
should be addressed, in quintuplicate,
to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), Washington, DC 20537, or any
being sent via express mail should be
sent to Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 2401 Jefferson Davis Highway,
Alexandria, Virginia 22301; and must be
filed no later than September 4, 2007.
VerDate Aug<31>2005
18:43 Jul 03, 2007
Jkt 211001
BILLING CODE 4410–09–P
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on May 8, 2007,
Austin Pharma LLC, 811 Paloma Drive,
Suite A, Round Rock, Texas 78664,
made application by renewal to the
Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of the basic classes of
controlled substances listed in schedule
I and II:
Drug
Manufacturer of Controlled
Substances; Notice of Application
Dated: June 26, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–12978 Filed 7–3–07; 8:45 am]
Drug Enforcement Administration
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Alexandria, Virginia 22301; and must be
filed no later than September 4, 2007.
Schedule
Marihuana (7360) .........................
Tetrahydrocannabinols (7370) .....
Alphamethadol (9605) ..................
Methadone (9250) ........................
Methadone Intermediate (9254) ...
Levo-alphacetylmethadol (9648) ..
Alfentanil (9737) ...........................
Remifentanil (9739) ......................
Sufentanil (9740) ..........................
Fentanyl (9801) ............................
I
I
I
II
II
II
II
II
II
II
The company plans to manufacture
the listed controlled substances in bulk
for distribution to its customers.
In reference to drug code 7360
(Marihuana), the company plans to bulk
manufacture cannabidiol as a synthetic
intermediate. This controlled substance
will be further synthesized to bulk
manufacture a synthetic THC (7370). No
other activity for this drug code is
authorized for this registration.
Any other such applicant and any
person who is presently registered with
DEA to manufacture such a substance
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections being sent via regular mail
should be addressed, in quintuplicate,
to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), Washington, DC 20537, or any
being sent via express mail should be
sent to Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 2401 Jefferson Davis Highway,
PO 00000
Frm 00082
Fmt 4703
Sfmt 4703
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on May 8, 2007,
Boehringer Ingelheim Chemicals, Inc.,
2820 N. Normandy Drive, Petersburg,
Virginia 23805, made application by
letter to the Drug Enforcement
Administration (DEA) to be registered as
a bulk manufacturer of
Lisdexamfetamine (1205), a basic class
of controlled substance listed in
schedule II.
The company plans to qualify as a
bulk manufacturer of the above listed
controlled substance.
Any other such applicant and any
person who is presently registered with
DEA to manufacture such a substance
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections being sent via regular mail
should be addressed, in quintuplicate,
to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), Washington, DC 20537, or any
being sent via express mail should be
sent to Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 2401 Jefferson Davis Highway,
Alexandria, Virginia 22301; and must be
filed no later than September 4, 2007.
Dated: June 26, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–12967 Filed 7–3–07; 8:45 am]
BILLING CODE 4410–09–P
E:\FR\FM\05JYN1.SGM
05JYN1
Agencies
[Federal Register Volume 72, Number 128 (Thursday, July 5, 2007)]
[Notices]
[Page 36728]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-12978]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Application
Pursuant to Sec. 1301.33(a) of Title 21 of the Code of Federal
Regulations (CFR), this is notice that on May 8, 2007, Austin Pharma
LLC, 811 Paloma Drive, Suite A, Round Rock, Texas 78664, made
application by renewal to the Drug Enforcement Administration (DEA) to
be registered as a bulk manufacturer of the basic classes of controlled
substances listed in schedule I and II:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Marihuana (7360)........................... I
Tetrahydrocannabinols (7370)............... I
Alphamethadol (9605)....................... I
Methadone (9250)........................... II
Methadone Intermediate (9254).............. II
Levo-alphacetylmethadol (9648)............. II
Alfentanil (9737).......................... II
Remifentanil (9739)........................ II
Sufentanil (9740).......................... II
Fentanyl (9801)............................ II
------------------------------------------------------------------------
The company plans to manufacture the listed controlled substances
in bulk for distribution to its customers.
In reference to drug code 7360 (Marihuana), the company plans to
bulk manufacture cannabidiol as a synthetic intermediate. This
controlled substance will be further synthesized to bulk manufacture a
synthetic THC (7370). No other activity for this drug code is
authorized for this registration.
Any other such applicant and any person who is presently registered
with DEA to manufacture such a substance may file comments or
objections to the issuance of the proposed registration pursuant to 21
CFR 1301.33(a).
Any such written comments or objections being sent via regular mail
should be addressed, in quintuplicate, to the Drug Enforcement
Administration, Office of Diversion Control, Federal Register
Representative (ODL), Washington, DC 20537, or any being sent via
express mail should be sent to Drug Enforcement Administration, Office
of Diversion Control, Federal Register Representative (ODL), 2401
Jefferson Davis Highway, Alexandria, Virginia 22301; and must be filed
no later than September 4, 2007.
Dated: June 26, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. E7-12978 Filed 7-3-07; 8:45 am]
BILLING CODE 4410-09-P